Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation

Hereditary transthyretin‐mediated (hATTR) amyloidosis, or ATTRv amyloidosis, is a progressive disease, for which liver transplantation (LT) has been a long‐standing treatment. However, disease progression continues post‐LT. This Phase 3b, open‐label trial evaluated efficacy and safety of patisiran i...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Hartmut H., Wixner, Jonas, Planté‐Bordeneuve, Violaine, Muñoz‐Beamud, Francisco, Lladó, Laura, Gillmore, Julian D., Mazzeo, Anna, Li, Xingyu, Arum, Seth, Jay, Patrick Y., Adams, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310767/
https://www.ncbi.nlm.nih.gov/pubmed/35213769
http://dx.doi.org/10.1111/ajt.17009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310767/
https://www.ncbi.nlm.nih.gov/pubmed/35213769
http://dx.doi.org/10.1111/ajt.17009

Ejemplares similares